Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.
AARD has been the topic of a number of other reports. Royal Bank of Canada decreased their price target on Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Morgan Stanley initiated coverage on Aardvark Therapeutics in a research note on Monday, March 10th. They issued an "overweight" rating and a $29.00 price target on the stock. Bank of America raised their price target on Aardvark Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 price target on shares of Aardvark Therapeutics in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $31.25.
Check Out Our Latest Research Report on Aardvark Therapeutics
Aardvark Therapeutics Stock Down 2.9%
Shares of AARD stock traded down $0.32 during mid-day trading on Friday, reaching $10.74. The stock had a trading volume of 14,774 shares, compared to its average volume of 97,036. Aardvark Therapeutics has a 12-month low of $4.88 and a 12-month high of $19.58. The firm's 50-day moving average is $9.83.
Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.01).
Hedge Funds Weigh In On Aardvark Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Walleye Capital LLC acquired a new position in Aardvark Therapeutics during the 1st quarter worth approximately $88,000. Goldman Sachs Group Inc. bought a new stake in shares of Aardvark Therapeutics in the 1st quarter valued at approximately $153,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Aardvark Therapeutics in the 1st quarter valued at approximately $1,878,000. Braidwell LP bought a new stake in shares of Aardvark Therapeutics in the 1st quarter valued at approximately $3,755,000. Finally, Cormorant Asset Management LP bought a new position in Aardvark Therapeutics during the 1st quarter worth $6,009,000.
About Aardvark Therapeutics
(
Get Free Report)
Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
See Also
Before you consider Aardvark Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.
While Aardvark Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
